Search

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Livestock

We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

Patient Assistance Program

BI Cares Patient Assistance Program Error

Protocols to Trim Mastitis in your Herd | Boehringer Ingelheim US

Read more on how the Boehringer Ingelheim mastitis grading chart protocols lead to creating better informed mastitis treatment decisions in livestock.

Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia

Funding Opportunities

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

Employees join #stayhomeandfoster movement

A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters

Discover our longstanding love for gardening and how it started with Schatzi’s chives.

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US

Click here to learn more about steps that pet owners can take to help prevent Lyme Disease in dogs.

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Partnering Purpose: BI Gives Back | Boehringer Ingelheim US

Hear from Sheila Denton, Senior Vice President, General Counsel and Corporate Secretary, on the importance of giving back to our communities.

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Embracing Differences: Our journey to diversity, equity, and inclusion

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Livestock

We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

Patient Assistance Program

Protocols to Trim Mastitis in your Herd | Boehringer Ingelheim US

Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia

Funding Opportunities

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

Employees join #stayhomeandfoster movement

A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Partnering Purpose: BI Gives Back | Boehringer Ingelheim US

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Embracing Differences: Our journey to diversity, equity, and inclusion